Read on Twitter
After weeks of donating the antiviral drug remdesivir to hospitals with severely ill coronavirus patients, the drug’s maker, Gilead Sciences, announced that it has settled on a price: $390 per vial, which works out to be roughly $2,340 per treatment course https://nyti.ms/38cdKjT
Until recently remdesivir was the only drug shown to help severely ill Covid-19 patients. But the benefits were modest, and the drug did not improve survival in those patients. Read more here. https://nyti.ms/38cdKjT
Gilead Sciences will distribute remdesivir under an unusual agreement with the U.S. government that establishes nonnegotiable prices and prioritizes American patients, health officials announced https://nyti.ms/38bX4ZT
House Democrats passed a bill to cap Americans' health insurance costs and give the government power to negotiate drug costs hours after the Trump administration announced it had secured remdesivir courses. Gilead Sciences is charging $2,340 per course. https://nyti.ms/2BMyYsy
